



Declaration Supporting Incentives for Medical Innovation

To U.S. Government Leaders:

The undersigned support U.S. policy incentives, particularly intellectual property (IP) protections, for medical innovators to continue lifesaving research.

In the U.S., our culture of innovation is bolstered by strong IP protections. These incentives inspire individuals to large biopharmaceutical companies to develop medical solutions that can lead to a better quality of life and are part of a thriving economy. Strong biopharmaceutical IP rights encourage investments in innovative new treatments that bring hope to patients worldwide. Without these protections, biopharmaceutical companies will have fewer incentives to embark upon the lengthy, uncertain, and expensive research and development process required to bring medicines to patients.

IP-intensive industries employ, directly and indirectly, more than 30 percent of the U.S. workforce, or 40 million workers across the country, with 3.4 million supported by the biopharmaceutical industry. The U.S. share of new chemical entities introduced from 2001-2010 was 57 percent. More medicines are researched and introduced in the U.S. than any other country. France, Germany, Switzerland and UK combined accounted for only 33 percent of new chemical entities introduced. There are currently 3,400 medicines in clinical development in the U.S., up from 2,400 in 2005. This is encouraging news that a U.S. industry is focused on finding new treatments for patients here and abroad with more than 800,000 direct employees of the pharmaceutical industry working on these cures.

On behalf of the organizations we represent, we support maintaining strong incentives for U.S. medical innovators. As discussions of U.S. debt and trade policy intensify, we urge policymakers to maintain strong IP protections. Strong biopharmaceutical IP rights – including the current U.S. law providing data protection for innovative biologics – should not be threatened in domestic policy or in international trade negotiation concessions.

Further, many of America's biopharmaceutical researchers have already faced tough cuts due to sequestration – therefore we urge U.S. policymakers to consider other ways to achieve a balanced budget, without reducing incentives for innovation – helping protect millions of jobs and provide hope for millions of patients that rely on new medicines.

Signed:

Action CF

AIDS Connecticut

Alabama Bio

Alzheimer's and Dementia Alliance of Wisconsin

American Autoimmune Related Diseases Association



American Society of Plastic Surgeons
Analtech, Inc.
Arizona Bioindustry Association
Biocom
BioBuzz Workforce Foundation, Inc.
BioFlorida
BioForward
BioHouston
BioNJ
Bioscience Association of North Dakota
BioUtah
California Healthcare Institute
Cambridge Chamber of Commerce
Center for Health Care Services
Chamber of Commerce of Eastern Connecticut
Coalition of Texans with Disabilities
Colorado BioScience Association
Community Health Charities of Florida
Community Health Charities of Iowa
Community Health Charities of Wisconsin
Connecticut Business & Industry Association (CBIA)
Connecticut United for Research Excellence, Inc. (CURE)
D'Souza and Associates
Delaware HIV Consortium
Delaware State AFL-CIO
Denver Metro Chamber of Commerce



Dia de la Mujer Latina

Economic Alliance Snohomish County

ENDECE, LLC

Endometriosis Association

Florida State Hispanic Chamber of Commerce

FluGen Inc.

Georgia Bio

Global Pharma Analytics, Inc.

Global Reach Internet Productions, LLC

Graves' Disease & Thyroid Foundation

Greater New Haven Chamber of Commerce

H.E.A.L.S of the South (Hepatitis Education, Awareness and Liver Support)

HealthCare Institute of New Jersey (HINJ)

Illinois Biotechnology Industry Organization

Illinois Chamber of Commerce

Illinois Manufacturers' Association

Indiana Health Industry Forum

Indiana Manufacturers Association

Information Technology and Innovation Foundation

The International Foundation for Autoimmune Arthritis

Iowa Biotechnology Association

Kentucky BioAlliance

Latino American Chamber of Commerce of Connecticut

LifeScience Alley

Lupus Foundation of America- DC/MD/VA Chapter

Lupus Foundation of Mid and Northern New York, Inc.

U.S. for Medical Innovation

2013



Massachusetts Association for Mental Health

Massachusetts Chamber of Commerce

MedCara Pharmaceuticals

Mental Health America of Indiana

Metropolitan Milwaukee Association of Commerce

NAMI Illinois

New Jersey Mayors Committee on Life Sciences

New Mexico Biotechnology & Biomedical Association

NewYorkBIO

North Carolina Biosciences Organization

North Carolina Biotechnology Center

Old North Medical Society

Omic BioSystems

Prevent Blindness Mid-Atlantic

Rio Grande Valley Diabetes Association

Rural Technologies Inc.

Rush to Live

Salt Lake Chamber of Commerce

Salud USA

SCBIO

Seattle Metropolitan Chamber of Commerce

Sequella, Inc.

Shelby County DevelopSource

SilcsBio, LLC

South Dakota Biotech

South Shore Chamber of Commerce

U.S. for Medical Innovation

2013



Tech Council of Maryland

Texas Association of Business

Texas BioAlliance

Texas Healthcare and Bioscience Institute

The Texas Life Science Foundation

Texas Nurse Practitioners

US Pain Foundation

Vietnam Veterans of America

Virginia Biotechnology Association

Virginia Chamber of Commerce

Virginia Small Business Partnership

Washington Biotechnology & Biomedical Association

Wisconsin Manufacturers and Commerce